

Illuminate EFX™

360° Skin renewing solution



Illuminate EFX™

INCI: Propanediol (and)
Hydroxycinnamic Acid
CAS #: 57-55-6, 7400-08-0
EC #: 200-338-0, 231-000-0

Antioxidant

Improves the appearance of skin discoloration

Improves Texture & Tone

Improves skin radiance and brightness

Improves the appearance of fine lines & wrinkles

Recommended applications



Skin Care



Body Care



China IECIC
2015



VEGAN




ISO
ISO9001:2015 - NOI
80-100%

[1] Y.K. Seo, et. al., "Effects of p-coumaric acid on erythema and pigmentation of human skin exposed to ultraviolet radiation" Clin. and Exp. Derm., 36, 260-266 (2010)

Vantage

Hydroxycinnamic acid – an effective anti-oxidant

HCA is an excellent anti-oxidant as seen by the high ORAC score.



Method


Test – broad-spectrum anti-oxidant analysis by comprehensive ORAC 6.0 assay

Measurement – antioxidant capacity against six primary reactive oxygen species peroxyl, hydroxyl, peroxy nitrite, superoxide anion, singlet oxygen, and hypochlorite

Results in micromole Trolox Equivalency per gram (or milliliter) of a test material.


Inhibition of Mushroom Tyrosinase

HCA inhibits mushroom tyrosinase by 97% and was more effective than Kojic acid



Principle

Tyrosinase - key enzyme in the synthesis of melanin from Tyrosine



Method



- Mushroom tyrosinase (Sigma, EC 1.14.18.1, activity 3960 units/mg) solution and the test compound or benchmark were mixed in a spectrophotometer cell using Phosphate buffer
- Test compound HCA (0.04% or 0.0025%) equivalent to Illuminate EFX™4 at 0.3% or 0.02% respectively
- Benchmark – Kojic acid (0.04% or 0.0025%)
- Equipment – UV-visible spectrophotometer
- Absorbance read continuously for 30 minutes.

Inhibition of Human Tyrosinase

HCA inhibits Human tyrosinase in reconstructed human skin model by 65%


Method

- Reconstructed human epidermis (RHE) were topically treated (n=3) with 5 mg/cm² medium containing Hydroxycinnamic acid - 0.04 and 0.08% final concentration (equivalent to HCA at 0.3% or 0.6% respectively)
- Incubation period: 7 days with test compounds or no treatment (control).
- Method for image capture: Fluorescence intensity was measured by epifluorescence microscopy and values were normalized to the epidermal surface.
- RHE treated with HCA at all concentrations did not show any loss of viability



Fluorescence staining : Blue - DAPI Stain for cell nuclei. Red = Cy3 conjugated solution for tyrosinase activity.

Principle



Effect on UV-induced Erythema

HCA prevents UV-induced erythema by 77% and was more effective when used prior to UV exposure




The control and 1.5% PCA cream products were applied twice daily to the skin of the forearm of 21 subjects before and after ultraviolet (UV) irradiation to determine whether they could prevent erythema formation. Skin color was measured by L*a*b* and Spectrophotometer CM2002 followed by ITA calculation,



Legend	Group	Day -7 to Day 0	Day 0	Day 1 thru 21
—●—	Untreated	No treatment	Irradiation	No treatment
—■—	Control	Control cream	Irradiation	Control cream
—▲—	PCA post irradiation	Control cream	Irradiation	PCA cream
—◆—	PCA cream	PCA cream	Irradiation	PCA cream

Change in Erythema Index




Illuminate EFX™

360° Skin renewing solution

Appearance	Light Yellow Liquid
Odor	Mild
Preservative system	None
Storage & Handling	Store in cool dark place
Recommended Use Level	1-3%

Expert clinical grading of skin attributes

A statistically significant improvement was observed for the product at 15 minutes after one application and after four and eight weeks of 2x/day product use for Skin Tone Evenness, Radiance/Brightness/Luminosity and Skin Texture/Smoothness compared to baseline



Assessment of skin tone benefits

Image analysis indicates a clear improvement in skin radiance at 4 and 8 weeks



All data, including the formulations and procedures discussed herein, to the knowledge of Vantage™, are believed to be correct, reliable and accurate. Please note, however, that Vantage™ does not warrant or guarantee any accuracy, reliability or completeness of the information contained herein. It is the user's responsibility to determine the suitability and completeness of such information for the user's particular use (including performing any necessary confirmatory tests). Vantage™ is not responsible or liable for any loss or damage that may occur from the use of this information, nor do we warrant against any patent infringement. Nothing contained herein shall be construed as providing any permission, recommendation, or inducement to practice any patented invention without permission of the patent owner.

060723

Vantage

www.vantagegrp.com